🏆 This tiny biotech firm has blown it out of th e water in 2024! Will 2025 be another winning year ?

2024 has been a record year for BSEM’s financial results making it no surprise that Zack’s Small Cap Research has a BULLISH price target of $32.50!

The biotech space could be looking at another exciting year of growth in 2024 and one company to keep your eyes on is BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care. BSEM is driving innovation in the wound care space and recently announced a significant patent. This is the first and only patent granted for use in tabular fenestrated allografts, which will support the company’s commercial efforts and expands its IP portfolio. With 27 patents pending and 42 issued, BioStem has a strong portfolio across the wound care landscape that will protect the company as it forges ahead in the market. This is a company addressing two multi-billion dollar markets and has seen record breaking quarterly results all year!
BSEMrecently released its 3Q2024 financial results, which continued to impress as revenues for the quarter bested estimates at $82.6 million and the gross profit margin moved to 95% from 91% in the year ago period. Net income was $0.32 per share, up from a loss a year ago and also above analyst estimates.BSEM has been reporting a string of better-than-expected results as company management continues to hit on all cylinders.Included in the several positive catalysts in 2024 were study results that showed the company’s signature technology, BioREtain, showing superior performance over the traditional standard of care! BioStem’s products are proving to be better over existing treatments and the company is accelerating commercial growth. There’s a good reason why Zack’s SCR keeps lifting its price target on the company and believes BSEM is still undervalued!

See why 2025 could be another breakout year of growth for BSEM and its shareholders!

This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $5200 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between January 24, 2025 and January 30, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com